Advanced search    

Search: authors:"Koki Aihara"

5 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

H3F3A K27M mutations in thalamic gliomas from young adult patients

Introduction Mutations in H3F3A, which encodes histone H3.3, commonly occur in pediatric glioblastoma. Additionally, H3F3A K27M substitutions occur in gliomas that arise at midline locations (eg, pons, thalamus, spine); moreover, this substitution occurs mainly in tumors in children and adolescents. Here, we sought to determine the association between H3F3A mutations and adult...

MOLECULAR EPIDEMIOLGOY

BACKGROUND: Several studies have observed a change in MGMT silencing and IDH1 mutation in secondary glioblastomas (sGBMs). However, reports about the prognostic value of promoter methylation of the MGMT gene and IDH mutations in sGBMs are few in number. METHODS: The study involved primary and secondary tumor tissue samples from 89 GBMs pts (P/S: 42/47) diagnosed and treated...

OMICS AND PROGNSTIC MARKERS

Although histopathological diagnosis is essential in decision of therapeutic strategy for gliomas, sometimes the tumors diagnosed in one histological entity show thoroughly different clinical courses. This phenomenon is believed to be due primarily to the presence of the genetic subgroup. In fact, relationship between treatment response and certain genetic characteristics is...

LAB–OMICS AND PROGNOSTIC MARKERS

We examine traditional tumor markers MIB-1 proliferation index (PI), microvascular density (MVD), 1p19q chromosomal co-deletion, or the emerging biomarker isocitrate dehydrogenase isoform 1 (IDH-1) and molecular markers of hypoxia including HIF-1α, VEGF, GLUT-1, and CA-IX and the University of California – San Francisco (UCSF) preoperative grading system for prediction of...